TriApex Express | Innovative Research Exchange at SOT 2025
Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in ...
Le Lézard11h
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization. In 2024, Akeso ...
Temasek’s 65 Equity makes Europe foray with Swiss pharma merger
It is financing Healthcare Advanced Synthesis’ acquisition of Cerbios-Pharma and taking a 40 per cent stake in merged entity.
65 Equity Makes Europe Foray With Swiss Pharma Merger
Asset manager 65 Equity Partners is backing Swiss pharmaceutical ingredient maker Healthcare Advanced Synthesis SA’s ...
The Business Times6h
Temasek-backed 65 Equity Partners makes Europe foray with Swiss pharma merger
LONDON] Asset manager 65 Equity Partners is backing Swiss pharmaceutical ingredient maker Healthcare Advanced Synthesis’ (HAS ...
Frontiers22h
Potential Biomarkers, Drug Targets, and New Therapeutic Approach in Intracavitary Cancer Therapy
Intracavitary tumors, including those originating from the respiratory tract, gastrointestinal (GI) tract, and urinary tract, mainly consist of epithelial cancers sharing similar characteristics, such ...